New drug for RAS-mutant advanced solid tumors
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called GFH276 for people with advanced solid tumors that have a RAS mutation. It aims to see if the drug is safe and effective against these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You are able to do your daily activities with little or no help (ECOG 0 or 1)
- You have a tumor with a mutation in the RAS gene (like KRAS, NRAS, or HRAS)
- You have not been treated before with a drug that targets all RAS mutations
- You do not have active brain metastases or active hepatitis B/C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
This trial tests a new drug called GFH375, either alone or combined with other treatments, for advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if this targeted approach can slow or shrink your cancer better than standard treatments.
This trial tests a new drug called GFH276 combined with either cetuximab or chemotherapy for people with certain cancers that have a specific genetic change called a RAS mutation. It focuses on solid tumors and pancreatic cancer (PDAC) and aims to see if the combination is safe and effective.
This trial tests a new oral medication (GFH375) for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the drug can shrink tumors or slow cancer growth.
This trial tests whether combining two experimental drugs (GFH375 with GFS202A or GFH276) works better than one drug alone for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. It may offer a new option for those who have already tried other treatments.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.